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Cyomegalovirus (CMV) infections are a major cause of morbidity and even mortality in im-
munocompromised hosts such as transplant recipients and patients with the Acquired Immuno-
deficiency Syndrome (AIDS). CMV-seronegative transplant recipients can largely be protected
against primary CMV infections by using blood products and grafts from seronegative donors.
Cytomegalovirus has the capacity to establish a latent infection after a primary infection. An
intact host cellular immwrity is important for keeping CMV in latency. Reactivation of latent
CMV can be achieved by affecting the immune system with immunosuppressive drugs or
allogeneic stimuli.
Most of the kidney transplant recipients are already CMV-seropositive before allografting,
and the majority of active CMV infectiorn after transplantation are secondary CMV infections
caused by the suppression of host's cellular immunity after institution of immunosuppressive
therapy. Better understanding of host-associated factors for the outcome of secondary CMV
infections might contribute to the prevention of serious CMV recrurences after transplantation
and give insight in the surveillance mechanisms which keep latent CMV under control in
immunocompromised hosts.
The basic concept underlying our study is that pre-existent virus-specific host immunity
against CMV-infected cells constitutes an important surveillance mechanism against recurrence
of CMV infection in latently CMV-infected hosts. A functionally intact afferent arm of the
CMV-specific immune response is needed for the activation of the efferent arrn" i.e. the rapid
recruitrnent of CMV-speci-fïc cytotoxic T lymphocytes and the production of lymphokines,
once reactivation of latent CMV threatens or has already occurred
Thus we srudied in immunocompromised hosts conditions that might exert inÍIuences on
host immunity against CMV-infected cells or on the outcome of recwrent CMV infections,
such as blood transfusions and genetic host factors.
CMV-specific cellular immunity was evaluated with the use of lymphocyte proliferation or
reactivity (LR) tests. Cytomegalovirus-specific T memory lymphocytes are activated and
proliferate in these in vitro cultures of peripheral blood mononuclear cells after stimulation
with cell- associated or cell-free CMV antigens.
In all sfudies virus-specific cellular immunity against CMV-infected cells wÍrs also
compared with the immtrne Íesponse against circulating CMV particles in immunocompetent
and immunocompromised hos ts.
Because of the reciprocal relationship between CMV infection and host's general cellular
immunocompetence, also tests for general cellular immunity were performed in our study
population.
The study population consisted of immunocompromised hosts who were at risk for a symp-
tomatic CMV recuÍrence or experienced a secondary CMV infection. They were recruited
from CMV-seropositive kidney transplantation candidates and recipients. Immunocompetent
hosts who experienced a symptomatic primary CMV infection recently or one to fïve yeÍrs
before, and healthy latently CMV-infected controls without a history of symptomatic CMV
disease, were also investigated.
In clwpter / a brief review about CMV infections is presented. Fundamental properties of
CMV and clinical signiÍicance of CMV infections, in particular after kidney transplantation,
are described in the sections 1.1 and 1.2. Non-specific and virus-specific immunological host
defence mechanisms against CMV infection, and the virus-induced immunosuppressive ffects
are briefly discussed in the sections 1.3 and 1.4. In section 1.5 some aspects of CMV latency
and recurre,nce are discussed. The aims of the study are described in section 1.6.
l l l
In clapter 2 the development and maintenance of the cellular immune response against cell-
associated CMV antigens (CI{VFF) was investigated in non-immunocompromised hosrs
shortly after outbreak of a symptomatic primary CMV infectiorL during the year thereafter, and
one to five years later.
Lymphocyte responses against CMVFF parallelled the developmenr of responses against
cell-free CMV antigens (CMV virions), i.e. severely depressed responses in rhe first two
months of symptomatic CMV infection, followed by a gradual increase to normal levels in the
year thereafter.
In the acute phase of the disease qualitative diÍïerences existed between lymphocye
responses to CMVFF and CMV virions. This was noticed by a lack of correlarion between
these responses. Some patients even showed positive lymphocyte responses against CMVFF
but no responses to CMV virions. Development of cellular immunity to CMV-induced antigens
on infected cells prior to that to CMV virions might be biologically imporranr for gerring CMV
under conftol, i.e. in latency.
One to five years after a symptomatic primary CMV infection high lymphocyte reactivities
against CVIVFF and CMV virions were found, indicating a continuous boostering of CMV-
specific cellular immunity by endogenous or exogenous CMV or a selection of high respon-
ders in the group of previously symptomatically CMV-infected immunocompetent hosts.
After primary CMV infection general cellular immunocompetence was suppressed. This
was revealed by depressed lymphocyte responses to mitogens, allogeneic lymphocytes and
microbial recall antigens in the acute phase of the infection, with restoration to normal levels
thereafter. We forurd, in contrast with previous reports, a more prolonged suppression of lym-
phocyte respoÍrses to Concanavalin A (Con A) persisting upto one to five years after a primary
CMV infection. This suggests longlasting immunosuppressive effects of a symproma-tic
Primary CMV infection on the cellular immwrocompetence of non-immunocompromised
hoss.
In the chapters 3 and 4 the maintenance of CMV latency and the long-term immunological
consequences of secondary CMV infectbns were investigated.
The patienm srudied were CMV-seropositive kidney allograft recipients wirh a grafr swvival
of at least two years who were on a stable maintenance immunosuppressive regime for more
than one year.
The results showed that recipients with an intrinsic capacity to maintain their CMV
clinically in latency after ransplantation had normal virus-specific cellular immunity to
infected target cells i.e. respons€s comparable with those of healthy CMV-seropositive con-
trols. Long-teÍïn renal allograft survivors who experienced a symptomatic secondary CMV
infection within the first 6 months after allografting had depresse<! immuniry against CMV-
infected cells (chapter 3).
Further results with respect to general host cellular immunocompetence showed that
patients with previous symptomatic secondary CMV infections had depressed lymphocyte
proliferations to mitogens (phytohemagglutinin, PHA, and pokeweed mirogen, PWIO,
microbial recall antigens and pooled allogeneic lymphocytes (mixed lymphocyre cuhures,
IvILC).
The alloimmune responses and the lymphocyte responses to cell-associated CMV antigens
were positively correlated with each other in these secondarily CMV-infected recipients.
Furthermore these responses both increased with prolonged graft survival i.e. time after
infection (chapter 4).
These associations are of particular interest, especially since recently an immunologic cross-
reactivity between epitopes on immediate-early cell-associated CMV antigens and the s-chain
of the HLA-DR molecule has been sugge.sted. This immunologic cÍoss-reactivity may also be
reflected in a suppression of the lymphocyte response to CMV-infected cells as well as in a
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ri/e put forward the hlpothesis that this suppression of CMV-specific and general cellular
immuniry induced by secondary CMV infection appears to exist for years and might contribute
to allograft tolerance in kidney uansplant recipients.
In a prospective study we analysed the inÍluence of genetic host factors on incidence and
severity of CMV infectioÍls after kidney transplantation (chapter 5.).
The results showed that HLA-DRw6 positive (DRwO*1 recipients had a higher susceptibility
for posttransplant CMV infections than otherwise comparable DRw6 negative @Rw6-)
recipients. Furthermore, DRw6+ secondarily CMV-infected recipients showed an increased
incidence of symptomatic CMV disease and CMV excretion during the follow-up period of
one yeaÍ after allografting.
Notably, the other HLA class II antigens were not associated with severity or incidence of
posttransplant CMV infections.
We conclude that the DRw6-associated susceptibility is likely a CMV-specific phenomenon
because there were no associations with the incidence of (recurrent) herpes simplex virus
infections after transplantation.
The inÍluence of blood trarsfusions on CMV-specific and general cellular immunity was
investigate d (chapte r 6.).
The srudy group consisted of CMV-seropositive candidates for kidney ransplantation. The
results showed a re,markably high incidence of "non-responders" to non-stmctural or early
(CMVFF-EA) as well as to late or strucrural cell-associated CMV antigens (CMVFF-LA)
among transfused patients.
We found that in the group of previously trarsfused patients general cellular immuno'
competence was also impaired. This was reflected by a high incide,nce of non-responders in
delayed tlpe skin reactivity tests after de novo sensitization with dinirochlorobenzene
(DNCB) and low lymphocyte proliferation to microbial recall antigens and allogeneic
lymphocytes.
Blood transfusions (3 volumes of leukocytes containing, packed red cells) were given to
never nansfused, CMV-seropositive, transplantation candidates with the aim to improve kidney
allograft survival. This, incidentally, resulted in a somewhat depressed in vitro lymphocyte
response to CMVFF-LA and Con A. The allogeneic interactions induced by blood trans-
fusions, certainly, did not result in a significant boostering of pre-existing CMV-specific
cellular immunity in dialysis patients.
Lymphocyte responses to cell-free CMV antigens were not inÍluenced by blood trans-
fusions.
The association between HLA-DR antigens and CMV-specific and general cellular immunity
was studied in previously trarxfused CMV-seropositive kidney transplantation candidates
(chapter 7.).
HLA-DRw6 was associated with depressed immune responses against CVI-'F-EA and LA.
This phenomenon was not CMV-specific since DRw6 was also associated with disturbances in
general cellular immunity such as a high incidence of non-responsiveness to DNCB and
depressed lymphocyte responses to microbi al reca II -anti g ens.
The presence of Í{LA-DR4 was associated with high responsiveness to cell-associated
CMV antigens. Lymphocyte responses against CMV virions were not associated with DR
antigens.
The predictive value of pretraruplant memory lymphoycte responses to early and late cell-
associated and cell-free CMV antigens for the outcome of secondary CMV infections after
kidney trarsplantation was evaluated in a prospective study (chapter 8.).
1r3
The absence or presence of pretransplant lymphocyte responses to non-struchral or
smrcnrral cell-associated CMV antigens was not related with the incidence of posttransplant
symptomatic CMV reclurences. Absent immune reactivity against non-stmctural cell-
associated CMV antigens contributed to a productive CMV infection once a symptomatic
CMV infection had developed.
A prerransplant non-responsiveness to CMV virions was a risk factor for acquiring a
symptoÍnatic CMV recuÍrence after kidney transplantation, independently of the presence of
DRw6 antigen. DRw6- responders to CMV virions had the lowest incidence of symptomaric
secondary CMV infections during a follow-up period of one year after transplantation.
The severity of secondary CMV infections was not related to low or highresponders state of
host's general cellular immunocompetence before allografting.
Concludlng remarks
The normal immune responses against cell-associated CMV antigens in hosts who maintain
their CMV clinically in latency even under immunosuppressive therapy and allostimulation,
and the very high responsiveness against cell-associated CMV antigens in immunocompetent
hosts even years after a symptomatic primary CMV infection, support the hypothesis rhat
circulating memory T cells against CMV-infected cells have a surveillance role in the
prevention of recurrent CMV disease.
Pretransplant responders to early cell-associated CMV antigens have a much lower
incidence of productive CMV infections than non-responders to these antigens. Responders to
early and/or late cell-associated CMV antigens ro, however, not fully protected from
symptomatic CMV recurrences after kidney transplalrtation.
A genetically determined host factor, i.e. the presence of HLA-DRw6 phenoqpe, is a more
important risk factor for symptomatic secondary CMV infection. DRw6 is not only associated
with strongly suppressed immune responses to early and late cell-associated CMV antigens,
but also with depressed immune reactivity against other antigerrs in previously transfused
CMV-seropositive candidates for a kidney transplantation. It is possible that previously
received blood transfusions or previous primary CMV infections exert longlasting suppressive
inlluences on host's cellular immunocompetence particularly in DRw6 positive patients. Futher
studies are needed to explore these possibilities.
The absence of pretransplant responsiveness to circulating CMV particles is another risk
factcr for symptomatic CMV requrence, independe,lrt of the DRw6 status of the host.
Identification of recipie,nts at risk for a serious CMV recrurence after kidney transplantation
might help in the management of these recipients. Prophylactic measures such as specific
antiviral drugs, interferon, anri-Clvw hyperimmune globulin or interleukin-2 immunorherapy,
in order to prevent serious CMV disease after transplantation, could be applied more
selectively and more effectively in high risk patients when they are selected on their DRw6
status and the pÍesence or absence of preransplant memory responses against cell-free and
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